Final rules establish, for the first time, a Category 1 CPT code and reimbursement to physicians performing ablation of malignant prostate tissue with HIFU in the US Physician reimbursement for HIFU approximately 30% higher than cryotherapy and brachytherapy Hospital reimbursement for HIFU up

  Generated strongest total revenue quarter of 2020 Reported growth in HIFU procedure revenues year-over-year notwithstanding ongoing COVID-19 pandemic Completed sales to renowned healthcare institutions Mount Sinai Health System in New York and Keck Medical Center at the University of Southern

Partnership further extends the availability of EDAP’s High Intensity Focused Ultrasound (HIFU) technology to one of the largest markets in Europe Complementary to AB Medica’s extensive product portfolio which includes robotic surgery solutions as well as ExactVu LYON, France , November 17, 2020 --

LYON , France, November 10, 2020 --  EDAP TMS SA  (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the Jefferies Virtual London Healthcare Conference , which is being held November 17-19, 2020.  Presentation Details

Company to host conference call and webcast on Thursday, November 19 at 8:30 am EDT LYON, France , November 9, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the third quarter ended September 30, 2020

Call to be Held Tuesday, September 22 nd @ 8am Eastern Time LYON, France , September 15, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will host a key opinion leader (KOL) call on its two lead commercial products, Focal One ® and

LYON, France , September 9, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the HC Wainwright Virtual 22nd Annual Global Investment Conference , which is being held September 14-15, 2020 .  Presentation

       ·  First patients already treated as recruitment accelerates LYON, France , September 3, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first two patients have been treated in the company’s Phase 2 clinical trial assessing

Completed multiple Focal One sales to renowned U.S. and international health care institutions, including multiple Focal One™-ExactVu™ bundled sales Announced first two U.S. publications in Journal of Urology detailing positive outcomes from U.S. studies of HIFU for the successful partial-gland

Multicenter study to commence in September in France Reinforces company’s recent shift in strategic focus toward development of additional high-value HIFU tissue ablation indications LYON, France , August 25, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic